Boston Heart transforms the treatment of cardiovascular disease

Cherie Lucier, Senior Director, Corporate Identity and Communications, clucier@bostonheartdx.com

Through the acquisition of Boston Heart, Eurofins strengthens its clinical testing and genomic service offering with a strong entry in the specialised cardiology diagnostic segment. In combination with the acquisition of Viracor-IBT in 2014, this acquisiton gives Eurofins an excellent position in two important segments of the specialty diagnostic testing market, thereby significantly enhancing its overall capabilities focusing on preventing life-threatening diseases. Boston Heart also expands Eurofins' genomics capabilities with a promising selection of patient-focused tests and proprietary tests to clients in the pharmaceutical industry.

Cardiovascular disease (CVD) remains the number one cause of death in the U.S. Of those who die of heart attacks, 50 percent have normal LDL cholesterol. Nutrition and lifestyle management is the first line of defence in CVD, but it is not actively pursued by millions of patients. In addition, compliance with prescribed medication continues to be amajor problem. 

Since 2007, Boston Heart has been transforming the treatment of CVD by arming healthcare providers with diagnostic insights that give a more detailed view and new perspective on treatment plans. The Boston Heart exclusive programme measures a patient's HDL particle concentration, identifies the source of cholesterol production, provides guidance on the best treatment options and engages patients in a novel way.

The insights from Boston Heart's CLIA-certified advanced CVD laboratory tests allow individualised treatment reducing or even eliminating the "trial and error" medicine that many patients suffer through and a major reason for non-adherence to treatment plans. Boston Heart helps providers identify patients at true underlying risk of CVD by going beyond the "good" and "bad" cholesterol assessment to give a more complete and individualised picture of heart health. Boston Heart has a rich history in evidence-based medicine and research that supports its highly focused test menu not offered by any other laboratory. Patient reports help explain test results and treatment considerations in language and imagery that every patient can understand. All of the content in the reports is personalised to the individual patient providing their unique heart health story based on lab results from lipid, inflammation, metabolic and/or genetic tests. Boston Heart's fully integrated and scientifically designed nutrition and lifestyle management programme is supported by its team of registered dietitians accessible to patients by phone. This integrated programme has the power to engage patients differently and change the way providers and patients communicate about disease.

Boston Heart is providing an innovative and fresh approach to CVD patient management by using high value diagnostics to allow treatment and power personalised communication tools designed to improve health literacy, patient engagement and adherence to treatment plans.The result is better patient outcomes.

For more information, visit: www.bostonheartdiagnostics.com.